Related News

Home » Business » Manufacturing

Vertex set to sell milestone rights on hepatitis drug

VERTEX Pharmaceuticals Inc said yesterday it planned to sell rights to future milestone payments tied to progress in Europe for its high-profile experimental hepatitis C drug.

The payments would come from Johnson & Johnson, which licensed European rights to the drug, telaprevir, from Vertex three years ago. Vertex retains rights to the drug in North America.

The milestones anticipated for telaprevir in Europe include US$100 million related to regulatory filing and approval for telaprevir and US$150 million related to its launch.

Telaprevir is being observed in three studies with more than 2,200 patients in the United States and Europe.


Copyright © 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.

沪公网安备 31010602000204号

Email this to your friend